Preterm Labour Clinical Trial
Official title:
Three - Dimensional Ultrasound Estimation of Fetal Adrenal Gland Enlargement Compared to Assessment of Cervical Changes Alone & Prediction of Impending Preterm Birth
If the investigators could prove that three -dimensional ultrasound measurement of fetal adrenal gland volume can accurately predict the likelihood of preterm birth in patients having symptoms and signs of PTL , they would be able to use it as a valuable component for assessment and early management of high risk pregnant women for PTB which can be positively reflected on the risk of neonatal morbidity and mortality in those patients.
Preterm birth ( PTB) is one of the leading causes of neonatal morbidity and mortality Early
PTB (≤ 34 weeks' gestation) carries a 7-fold increased risk of Neonatal death . Following
PTB, survivors can experience significant long term cognitive, behavioral, emotional,
sensory, and motor deficits. Hence, there is growing interest in the identification of women
who are at Risk for spontaneous PTB. Many biophysical and biochemical markers have been
discovered to identify those women who are at risk for spontaneous PTB.
Unfortunately, none of the various maternal and fetal biomarkers such as:
cytokines, CRH, C-reactive protein, fetal fibronectin ,…. etc. are sufficiently sensitive or
specific to be used alone or in combination to help decrease the rate of preterm births.
Obviously, there's a need for an accurate method with high sensitivity and specificity for
prediction of preterm labor. So that an appropriate management or referral to a higher
center can be done to women likely to have PTB. Whereas unnecessary tocolytic therapy can be
avoided in women who are unlikely to have PTB. Convincing data have shown that 2-dimensional
(2D) ultrasound measurement of cervical length (CL) can identify women at risk for PTB.
Accordingly, CL is now widely used in clinical practice for risk estimation. However, as
understanding of the mechanisms of preterm labor (PTL) have evolved, obstetricians have
learned that, in some women, cervical shortening is a phenomenon that carries no increased
risk for prematurity. Therefore, the search for early and accurate markers that distinguish
between physiologic processes and abnormal activation of the labor cascade has been ongoing.
Literature has suggested that activation of the fetal hypothalamic-pituitary-adrenal axis
play a crucial rule in commencement of labor. A previous study demonstrated that three
-dimensional ultrasound measurement of fetal adrenal gland volume (AGV) may identify women
at risk for impending PTB. In a more recent study receiver operator characteristics (ROC)
curve analysis revealed that three -dimensional ultrasound measurement of (AGV) was superior
to two-dimensional ultrasound measurement of (AGV) for anticipation of PTB within 7 days of
the scan. The aim of this study is to investigate the utility of 3D fetal adrenal gland
volume measurement in the early prediction of PTB and to determine whether these
measurements could be combined with 2D ultrasound cervical assessment to improve the early
prediction of PTB.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01340222 -
Monocyte Chemotactic Protein-1 (MCP-1) Expressing Monocytes to Predict Preterm Delivery: PhenoMAP Study
|
N/A | |
Completed |
NCT00568113 -
N-Acetyl Cysteine for Prevention of Preterm Birth
|
Phase 4 | |
Not yet recruiting |
NCT04104984 -
Detection of Preterm Labour by Cervical Length
|
Early Phase 1 | |
Recruiting |
NCT02331199 -
Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity
|
Phase 3 | |
Completed |
NCT02092688 -
Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth
|
||
Completed |
NCT02284867 -
Are Uterine Natural Killer Cells Involved in the Initiation of Preterm Labor ?
|
N/A | |
Completed |
NCT01429545 -
Single Versus Combination Therapy in Acute Tocolysis
|
Phase 2 |